Publications for all Oxford Principal Investigators within the CAMS Oxford Institute are included here, please use the search functions for publications related to specific Principal Investigators.
Priorities for rapid and cost-effective vaccines to improve outbreak responses
Gilbert SC., (2025), PLOS Biology, 23, e3003114 - e3003114
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
Venkatraman N. et al, (2025), The Lancet Microbe, 100868 - 100868
Aerosol immunization with influenza matrix, nucleoprotein, or both prevents lung disease in pig.
Vatzia E. et al, (2024), NPJ vaccines, 9
Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine
Wee EG-T. et al, (2024), Vaccines, 12, 965 - 965
Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.
Flaxman A. et al, (2024), PLoS pathogens, 20
Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine.
Bissett C. et al, (2024), NPJ vaccines, 9
Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease.
Drury RE. et al, (2024), Nat Commun, 15
Predicting airway immune responses and protection from immune parameters in blood following immunization in a pig influenza model.
Gubbins S. et al, (2024), Frontiers in immunology, 15
ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface.
Ni T. et al, (2023), iScience, 26
Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters.
Port JR. et al, (2023), Nature communications, 14
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
Jenkin D. et al, (2023), The Lancet Infectious Diseases, 23, 956 - 964
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
Kaplonek P. et al, (2023), Nature immunology
COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats.
Hotez PJ. et al, (2023), BMJ global health, 8
Factors, enablers and challenges for COVID-19 vaccine development.
Excler J-L. et al, (2023), BMJ global health, 8
Vaccine access, equity and justice: COVID-19 vaccines and vaccination.
Privor-Dumm L. et al, (2023), BMJ global health, 8
ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface
Zhang P. et al, (2023)
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182